I
Initiator Pharma A/S
STO:INIT
Initiator Pharma A/S
STO:INIT
Price:
2.91
SEK
2.46%
Market Closed
Market Cap:
kr199.2m
Initiator Pharma A/S
Total Equity
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Initiator Pharma A/S
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Initiator Pharma A/S
STO:INIT
|
Total Equity
kr29.5m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Total Equity
kr5.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
28%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Equity
kr14.8B
|
CAGR 3-Years
163%
|
CAGR 5-Years
65%
|
CAGR 10-Years
50%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Total Equity
$15.8m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Equity
-€162.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Equity
kr13.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
20%
|
CAGR 10-Years
26%
|
|
No Stocks Found
Initiator Pharma A/S
Glance View
Initiator Pharma A/S is a clinical-stage biotechnology company, which engages in the development of novel therapeutics within the field of mono-amine reuptake transporters targeting central nervous system (CNS)-disorders. The firm focuses on developing drugs for treatment of erectile dysfunction.
INIT
Intrinsic Value
8.14
SEK
Undervaluation 64%
I
See Also
What is Initiator Pharma A/S's Total Equity?
Total Equity
14.8m
DKK
14.8m
DKK
Based on the financial report for Dec 31, 2024, Initiator Pharma A/S's Total Equity amounts to 14.8m DKK.
What is Initiator Pharma A/S's Total Equity growth rate?
Total Equity CAGR 5Y
8%
8%
Over the last year, the Total Equity growth was 32%. The average annual Total Equity growth rates for Initiator Pharma A/S have been -25% over the past three years , 8% over the past five years .
